The FDA vs. Peptides: The Truths About DSIP, Semax, & Epitalon

The FDA's Pharmacy Compounding Advisory Committee is reviewing whether popular peptides should be added to the list of allowable compounds for compounding pharmacies. In Part 2 of this series, Dr. Ashley Froese provides an objective medical breakdown of DSIP (Emideltide), Semax, and Epitalon. While many individuals report life-changing benefits for sleep, brain fog, and longevity, the FDA’s briefing documents point to gaps in standardized safety data, purity concerns, and potential long-term risks. Key Topics Covered: • DSIP (Emideltide): Neuropeptides, deep slow-wave delta sleep, cortisol regulation, and its history in opioid/alcohol withdrawal research • Semax: Mechanism of action via ACTH receptors, BDNF spikes for brain fog/stroke recovery, and the balance of glutamate levels • Epitalon: Epithalamin cellular research, telomere extension, pineal gland support, and the FDA’s stance on potential oncogenic risks • The Systemic Issue: The conflict between evidence-based standards, unregulated grey-market risks, and disenfranchised humans trying to heal Learn Peptides with Dr. Froese's Peptide Mastery Course: https://courses.drafroese.com/